IMS World Review

IMS World Review ExecutiveTM 201020TH ANNIVERSARY EDITION

WR Exec Summ A5 Landscape cvr 2010:Layout 1 28/06/2010 15:45 Page 1

iIMS World Review Executive™ 2010© 2010 IMS Health Incorporated or its affiliates. All rights reserved.

IMS World Review ExecutiveTM 2010 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2005 to 2009, including the breakdown of sales by regions, countries, therapeutic areas, products and companies.

This handy pocket-size guide will give company executives the opportunity to obtain the most accurate and consistent pharmaceutical sales data available on the market.

For its 20th Anniversary, IMS World Review ExecutiveTM has been enhanced to include additional datasets such as insights on Biologics and Generics. The format and layout have also been improved to allow this resource to be recognized as a unique global market overview.

IMS World Review ExecutiveTM also provides critical insights into the future which can be found in the new chapter called: “Global Pharmaceutical Outlook to 2014”. A combination of qualitative insights and top line forecasts allow the reader to understand the prognosis of the global pharmaceutical market.

IMS Health7 Harewood AvenueLondon NW1 6JBUnited KingdomTel: + 44 203 075 5888Mail: [email protected]

PrefaceIMS WORLD REVIEW EXECUTIVE™ 2010

ii IMS World Review Executive™ 2010© 2010 IMS Health Incorporated or its affiliates. All rights reserved.

The Information Service contained herein is confidential and provided subject to the IMS Health Information Services Standard Terms and Conditions. This Information Service is provided to the Client on a personal basis under a non-exclusive and non-transferable licence for the Client’s own direct benefit and use only, and may not be copied or divulged to any other party. Whilst every possible care has been taken in the preparation of this information, the publishers do not hold themselves responsible for any expressions of opinion or error or omission, or any action resulting therefrom.

© 2010. IMS Health Incorporated or its affiliates. All rights reserved

iiiIMS World Review Executive™ 2010© 2010 IMS Health Incorporated or its affiliates. All rights reserved.

Table of ContentIMS WORLD REVIEW EXECUTIVE™ 2010

PREFACE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . i

WORldWIdE PhARMACEuTICAl MARkETS - ESTIMATEd MARkET . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1Market Estimates by Region . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2Market Estimates for Top 30 Countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3Market Estimates for Other IMS Audited Countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5

REGIONAl & COuNTRY MARkET TRENdS - AudITEd MARkET . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9Worldwide Growth Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11North America Growth Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12Europe Growth Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13Africa, Asia & Australasia Growth Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16Latin America Growth Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19Five Year Growth Rates by Country . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20

WORldWIdE PhARMACEuTICAl CORPORATIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25Top 100 Worldwide Corporations - Worldwide Sales & Regional Market Share . . . . . . . . . . . . . . . . . . . . . . . . . . . 26Fastest Growing 50 Corporations - Five Year Worldwide Sales Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31

WORldWIdE ThERAPEuTIC AREAS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35Sub-Therapeutic Classes Analysis - Worldwide Sales & Regional Market Share . . . . . . . . . . . . . . . . . . . . . . . . . . . 36Top 50 Therapeutic Areas (ATC3) - Leading Corporations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74Fastest Growing 100 Therapeutic Areas - Five Year Worldwide Sales Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . 124

iv IMS World Review Executive™ 2010© 2010 IMS Health Incorporated or its affiliates. All rights reserved.

Table of ContentIMS WORLD REVIEW EXECUTIVE™ 2010

WORldWIdE PhARMACEuTICAl PROduCTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131Top 75 Worldwide Products - Worldwide Sales & Regional Market Share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132Fastest Growing 80 Products - Five Year Worldwide Sales Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145Top 50 New Active Substances - Five Year Worldwide Sales Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151Top 50 Biologics - Five Year Worldwide Sales Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155Top 50 Generic Products - Five Year Worldwide Sales Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158

GlOBAl PhARMACEuTICAl OuTlOOk TO 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167

APPENdICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169Estimated Market Universe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169Audited Market Universe & Panels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175IMS New Active Substance Definition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183IMS Generics Definition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185IMS Biologics Definition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189Sales Data Measures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192

CONTACT uS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195

1IMS World Review Executive™ 2010© 2010 IMS Health Incorporated or its affiliates. All rights reserved.

IntroductionWORLDWIDE PHARMACEUTICAL MARKETS - ESTIMATED MARKET

This section provides a sales data overview of the 2009 world pharmaceutical markets, using the Estimated Market Universe.

US$ sales values and growth rates from 2005 to 2009 are displayed for all regions as well as for all IMS audited countries, allowing you to understand the performance of each country market and their evolution over the years. To give you as complete a picture as possible, estimated sales through all distribution channels in all countries are shown (Market Estimates by Region), whether these channels are audited by IMS Health or not. These estimates are intended to include both prescription and most non-prescription products. We provide these estimates to put into perspective the information contained in all other sections of IMS World Review Executive™, which is based on IMS Health audit information only. For any country audited by IMS Health, the total market estimate is based on the audited figure, with allowances made for non-audited sectors of the market, based on information from IMS Health audits.

For non-audited markets we have used the technique of reverse evaluation of export statistics, export statistics of the major exporting countries are matched up with local import statistics. Retained local production is added in, to arrive at a total market estimate. Please refer to the Appendices to review all the countries included in the Estimated Market Universe.

2 IMS World Review Executive™ 2010© 2010 IMS Health Incorporated or its affiliates. All rights reserved.

USD Millions

Worldwide Pharmaceutical Market Estimate 2009 = $806.6 Billion

CHART 1

$48,654 LatinAmerica 6.0%

$201,795 Africa, Asia& Australasia 25.0%

$319,452North America 39.7%

$236,690Europe 29.3%

Revised Revised Revised Revised2009 2008 2007 2006 2005

Country $ (Bill) $ (Bill) $ (Bill) $ (Bill) $ (Bill)

North America 319.5 304.1 298.6 285.7 261.1

Europe 236.7 246.6 217.8 186.3 174.4

Africa, Asia & Australasia

201.8 179.2 155.1 137.2 133.5

Latin America 48.7 48.4 42.1 35.9 32.2

TOTAL WORLD MARKET ($ Billion)

806.6 778.3 713.6 645.0 601.2

GROWTH OVER PREVIOUS YEAR (%)

3.6% 9.1% 10.6% 7.3%

WORLDWIDE PHARMACEUTICAL MARKETS - ESTIMATED MARKETMarket Estimates by Region


WORLDWIDE PHARMACEUTICAL MARKETS - ESTIMATED MARKETMarket Estimates for Top 30 Countries

2009 Revised 2008 Revised 2007 Revised 2006 Revised 20052009 2009 Growth (%) 2008 Growth (%) 2007 Growth (%) 2006 Growth (%) 2005 Growth (%)

Rank Country $ (Mill) $ lCd $ (Mill) $ lCd $ (Mill) $ lCd $ (Mill) $ lCd $ (Mill) $ lCd

1 United States 300748 5 5 285285 2 2 280995 4 4 270108 9 9 247654 5 5

2 Japan 89865 17 6 77041 17 3 65730 3 4 63711 -6 -1 67741 5 7

3 Germany 41275 -2 4 41932 12 5 37278 16 6 32076 3 2 31100 7 8

4 France 40575 -5 1 42526 10 3 38495 16 6 33217 4 3 32041 7 7

5 China 31688 29 27 24545 39 27 17698 32 26 13441 16 13 11612 22 20

6 Italy 26857 -1 4 27169 12 4 24234 15 6 20989 5 4 19949 4 4

7 Spain 22818 1 6 22620 16 8 19563 19 9 16486 9 8 15129 8 8

8 United Kingdom 19843 -11 5 22234 -5 3 23368 14 5 20505 6 4 19433 -3 -2

9 Canada 18705 -0 6 18786 7 6 17590 13 6 15549 15 8 13489 15 7

10 Brazil 17403 4 13 16749 22 14 13708 25 11 10957 13 2 9687 37 13

11 Russian Federation 11442 -9 15 12609 38 35 9118 12 5 8132 41 35 5747 50 48

12 India 10405 7 19 9725 4 11 9314 25 13 7463 15 18 6503 12 9

13 Mexico 10399 -17 1 12576 0 2 12525 8 8 11598 5 6 11000 16 12

14 Turkey 10276 -4 16 10660 12 12 9508 29 17 7363 5 12 7009 54 46

15 South Korea 9472 -3 14 9756 -5 10 10287 14 11 9049 20 12 7547 27 13

16 Australia 9423 0 7 9388 11 10 8443 23 11 6843 3 4 6616 9 5

17 Greece 7537 4 10 7254 18 10 6124 28 18 4772 12 11 4249 13 13

18 Venezuela 6626 31 31 5050 33 33 3793 33 33 2862 30 32 2200 18 32

19 Poland 6601 -15 10 7794 27 9 6160 23 9 5022 9 4 4623 21 8

20 Belgium 6208 -2 3 6356 14 6 5565 15 6 4822 2 2 4709 4 4

21 Netherlands 5417 -8 -3 5914 4 -4 5712 16 7 4909 4 3 4709 3 3


IntroductionREGIONAL & COUNTRY MARKET TRENDS - AUDITED MARKET

This section provides a sales data overview of the 2009 world pharmaceutical markets, using the IMS Audited Market Universe.

US$ sales values and growth rates from 2005 to 2009 are displayed for all regions. Growth rates based on US$ from 2005 to 2009 are shown for all IMS audited countries, allowing you to understand the performance of each country market and their evolution over the years.

IMS Health’s pharmaceutical audits for individual countries serve as the main source of comparative sales data on the pharmaceutical industry. The audits are continuous, periodic market surveys based on statistically representative samples, the data from which provide regional and national estimates. In the major countries, the pharmaceutical audits incorporate transaction data from wholesalers giving rise to a near-census of the retail market.

Each country audit records the data according to local requirements. Therefore the way data is collected and held will vary from country to country. In the European countries and America, the majority of pharmaceuticals are dispensed or sold mainly through retail pharmacies and drug stores. Thus sampling at the retail pharmacy level in such countries will represent a major proportion of the total market. Consequently, most of the IMS Health audits are sampled through retail pharmacies. There are some exceptions, for example Japan (see Japan section).

The audits provide a comprehensive record of purchases of pharmaceuticals in each country. A number of retail pharmacies and wholesalers are chosen for sampling (sample size) and sales data is collected by IMS Health on a regular basis. This data is then projected to estimate sales for the total number of retail pharmacies in a country (this is referred to as the universe). With some variation in each country, the sales estimates shown represent direct and indirect purchases by retail pharmacies from pharmaceutical wholesalers and manufacturers.

It should be noted that, whilst IMS Health data is the most comprehensive source available to monitor sales through their retail channels, some products are more widely distributed and used in a hospital or clinic environment (for example oncology, diagnostic or specialist anti-infective treatments). For such products, IMS Health retailer-based audits do not provide comprehensive coverage, and supplementary data sources will be required to project these data to a total universe for these specialist products.

The sales data in IMS World Review Executive™ is calculated based on sales from manufacturer to wholesalers known as the ex-manufacturer price.

10 IMS World Review Executive™ 2010© 2010 IMS Health Incorporated or its affiliates. All rights reserved.

In many countries, including USA, Canada, Japan and throughout Latin America, these are estimated weighted average factors, which take into account varying margins and the direct/indirect sales mix. As market conditions change the conversion factors are updated by the local IMS offices. Changes in factors are not retroactively applied to historical data.

Data is collected in each country in local currency. This is converted into US Dollars using the prevailing average exchange rate for the quarter.

Please refer to the Appendices to review all the countries included in the Audited Market Universe.

IntroductionREGIONAL & COUNTRY MARKET TRENDS - AUDITED MARKET


2005 $567,9692006 $609,5262007 $670,4222008 $726,1642009 $751,027

0

100000

200000

300000

400000

500000

600000

700000

800000

2005

+12.3%+7.9%

+6.9%

+10.0%+7.6%

2006 2007 2008 2009

USD MillionsGrowth $ (%) AV Growth **AV Growth

Based on uS$ 2009 2008 2007 2006 2005 $ (%) $ (%)

Worldwide 3 8 10 7 8 7 7

NORTH AMERICA

5 2 5 9 6 5 5

EUROPE -4 12 16 6 8 7 7

A/A/A 12 15 12 2 12 11 11

LATIN AMERICA

2 15 17 15 19 13 13

REGIONAL & COUNTRY MARKET TRENDS - AUDITED MARKETWorldwide Growth Trends


This section provides a sales data overview of the 2009 leading pharmaceutical corporations, using the IMS Audited Market Universe.

US$ sales values and growth rates from 2005 to 2009 are displayed for the top 100 corporations, as well as their market share in North America, Europe, Africa-Australasia-Asia, and Latin America. Please refer to the Appendices - “Audited Market Universe and Panels” section - to view the countries included in each region.

This section also includes the fastest-growing 50 corporations, including US$ sales and growth rates over 2005 to 2009.

IntroductionWORLDWIDE PHARMACEUTICAL CORPORATIONS


IntroductionWORLDWIDE THERAPEUTIC AREAS

This section provides a sales data overview of the 2009 leading therapeutic areas, using the IMS Audited Market Universe.

US$ sales values and growth rates from 2005 to 2009 are displayed for all therapeutic classes at level 4, as well as their market share in North America, Europe, Africa-Australasia-Asia, and Latin America. Please refer to the Appendices - “Audited Market Universe and Panels” section - to view the countries included in each region.

This section also profiles the top 50 therapeutic areas at level 3, showing the leading 15 corporations. This is complemented by a view of the fastest-growing 100 therapeutic areas, including US$ sales and growth rates over 2005 to 2009.


IntroductionWORLDWIDE PHARMACEUTICAL PRODUCTS

This section provides a sales data overview of the 2009 leading pharmaceutical products, using the IMS Audited Market Universe.

US$ sales values and growth rates from 2005 to 2009 are displayed for the top 75 products, as well as their market share in North America, Europe, Africa-Australasia-Asia, and Latin America. Please refer to the Appendices - “Audited Market Universe and Panels” section - to view the countries included in each region.

This section also includes the fastest-growing 80 Products, including US$ sales and growth rates over 2005 to 2009.

Sales data over 2005 to 2009 is also provided for the top 50 New Active Substances, Generics and Biologics. Please refer to the Appendices to understand how IMS defines New Active Substances, Generics and Biologics.

ABOUT IMS

Operating in more than 100 countries, IMS Health isthe world’s leading provider of market intelligence tothe pharmaceutical and healthcare industriesWith $2.2 billion in 2009 revenue and more than 50 years of industry experience, IMS offersleading-edge market intelligence products and

services that are integral to clients’ day-to-dayoperations, including product and portfoliomanagement capabilities; commercial effectivenessinnovations; managed care and consumer healthofferings; and consulting and services solutions thatimprove productivity and the delivery of qualityhealthcare worldwide. Additional information isavailable at http://www.imshealth.com

IMS HEALTH®

7 Harewood Avenue London NW1 6JB UKTel: +44 (0)20 3075 5888www.imshealth.com

WR Exec Summ A5 Landscape cvr 2010:Layout 1 28/06/2010 15:45 Page 2

Documents

IMS World Review